BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: D'Antonio C, Passaro A, Gori B, Del Signore E, Migliorino MR, Ricciardi S, Fulvi A, de Marinis F. Bone and brain metastasis in lung cancer: recent advances in therapeutic strategies. Ther Adv Med Oncol 2014;6:101-14. [PMID: 24790650 DOI: 10.1177/1758834014521110] [Cited by in Crossref: 113] [Cited by in F6Publishing: 106] [Article Influence: 14.1] [Reference Citation Analysis]
Number Citing Articles
1 Ma C, Wu G, Zhu Q, Liu H, Yao Y, Yuan D, Liu Y, Lv T, Song Y. Long intergenic noncoding RNA 00673 promotes non-small-cell lung cancer metastasis by binding with EZH2 and causing epigenetic silencing of HOXA5. Oncotarget 2017;8:32696-705. [PMID: 28423732 DOI: 10.18632/oncotarget.16158] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
2 Hu F, Li C, Xu J, Guo J, Shen Y, Nie W, Zheng X, Wang L, Zhang H, Han B, Zhang X. Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients. Lung Cancer 2019;135:138-44. [PMID: 31446986 DOI: 10.1016/j.lungcan.2019.07.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
3 Prateep A, Sumkhemthong S, Karnsomwan W, De-Eknamkul W, Chamni S, Chanvorachote P, Chaotham C. Avicequinone B sensitizes anoikis in human lung cancer cells. J Biomed Sci 2018;25:32. [PMID: 29631569 DOI: 10.1186/s12929-018-0435-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Tang J, Ge QM, Huang R, Shu HY, Su T, Wu JL, Pan YC, Liang RB, Zhang LJ, Shao Y, Yu Y. Clinical Significance of CYFRA21-1, AFP, CA-153, CEA, and CA-199 in the Diagnosis of Lung Cancer Ocular Metastasis in Hypertension Population. Front Cardiovasc Med 2021;8:670594. [PMID: 34595214 DOI: 10.3389/fcvm.2021.670594] [Reference Citation Analysis]
5 Luo W, Liu X, Sun W, Lu JJ, Wang Y, Chen X. Toosendanin, a natural product, inhibited TGF-β1-induced epithelial-mesenchymal transition through ERK/Snail pathway. Phytother Res 2018;32:2009-20. [PMID: 29952428 DOI: 10.1002/ptr.6132] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
6 Fehrenbacher L, von Pawel J, Park K, Rittmeyer A, Gandara DR, Ponce Aix S, Han JY, Gadgeel SM, Hida T, Cortinovis DL, Cobo M, Kowalski DM, De Marinis F, Gandhi M, Danner B, Matheny C, Kowanetz M, He P, Felizzi F, Patel H, Sandler A, Ballinger M, Barlesi F. Updated Efficacy Analysis Including Secondary Population Results for OAK: A Randomized Phase III Study of Atezolizumab versus Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer. J Thorac Oncol. 2018;13:1156-1170. [PMID: 29777823 DOI: 10.1016/j.jtho.2018.04.039] [Cited by in Crossref: 97] [Cited by in F6Publishing: 104] [Article Influence: 24.3] [Reference Citation Analysis]
7 Feng H, Lu JJ, Wang Y, Pei L, Chen X. Osthole inhibited TGF β-induced epithelial-mesenchymal transition (EMT) by suppressing NF-κB mediated Snail activation in lung cancer A549 cells. Cell Adh Migr 2017;11:464-75. [PMID: 28146373 DOI: 10.1080/19336918.2016.1259058] [Cited by in Crossref: 28] [Cited by in F6Publishing: 28] [Article Influence: 5.6] [Reference Citation Analysis]
8 Jablonska PA, Bosch-Barrera J, Serrano D, Valiente M, Calvo A, Aristu J. Challenges and Novel Opportunities of Radiation Therapy for Brain Metastases in Non-Small Cell Lung Cancer. Cancers (Basel) 2021;13:2141. [PMID: 33946751 DOI: 10.3390/cancers13092141] [Reference Citation Analysis]
9 Yamada D, Takahashi K, Kawahara K, Maeda T. Autocrine Semaphorin3A signaling is essential for the maintenance of stem-like cells in lung cancer. Biochemical and Biophysical Research Communications 2016;480:375-9. [DOI: 10.1016/j.bbrc.2016.10.057] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
10 Proto C, Imbimbo M, Gallucci R, Brissa A, Signorelli D, Vitali M, Macerelli M, Corrao G, Ganzinelli M, Greco FG, Garassino MC, Lo Russo G. Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. Transl Lung Cancer Res 2016;5:563-78. [PMID: 28149752 DOI: 10.21037/tlcr.2016.10.16] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
11 Grumeretz S, Wilson CM. Evaluating the Risk of Pathologic Fracture in Metastatic Bone Disease. Rehabilitation Oncology 2021;39:E67-9. [DOI: 10.1097/01.reo.0000000000000265] [Reference Citation Analysis]
12 Labanca E, Vazquez ES, Corn PG, Roberts JM, Wang F, Logothetis CJ, Navone NM. Fibroblast growth factors signaling in bone metastasis. Endocr Relat Cancer 2020;27:R255-65. [PMID: 32369771 DOI: 10.1530/ERC-19-0472] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
13 Shonka N, Venur VA, Ahluwalia MS. Targeted Treatment of Brain Metastases. Curr Neurol Neurosci Rep 2017;17. [DOI: 10.1007/s11910-017-0741-2] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
14 Wang G, Chen J, Ma R, Xu W, Yan C, Niu C. Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases. Oncol Lett 2018;16:1696-700. [PMID: 30008855 DOI: 10.3892/ol.2018.8804] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Andratschke N, Kraft J, Nieder C, Tay R, Califano R, Soffietti R, Guckenberger M. Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC). Lung Cancer 2019;129:63-71. [DOI: 10.1016/j.lungcan.2018.12.009] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
16 Li WJ, Xue HX, You JQ, Chao CJ. Lung adenocarcinoma metastasis to paranasal sinus: A case report . World J Clin Cases 2022; 10(17): 5869-5876 [DOI: 10.12998/wjcc.v10.i17.5869] [Reference Citation Analysis]
17 Haznadar M, Diehl CM, Parker AL, Krausz KW, Bowman ED, Rabibhadana S, Forgues M, Bhudhisawasdi V, Gonzalez FJ, Mahidol C, Budhu A, Wang XW, Ruchirawat M, Harris CC. Urinary Metabolites Diagnostic and Prognostic of Intrahepatic Cholangiocarcinoma. Cancer Epidemiol Biomarkers Prev 2019;28:1704-11. [PMID: 31358519 DOI: 10.1158/1055-9965.EPI-19-0453] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
18 Nguyen PA, Chang CC, Galvin CJ, Wang YC, An SY, Huang CW, Wang YH, Hsu MH, Li YJ, Yang HC. Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan. Cancer Sci 2020;111:2965-73. [PMID: 32441434 DOI: 10.1111/cas.14493] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
19 Fu L, Deng R, Huang Y, Yang X, Jiang N, Zhou J, Lin C, Chen S, Wu L, Cui Q, Yun J. DGKA interacts with SRC/FAK to promote the metastasis of non-small cell lung cancer. Cancer Lett 2022;532:215585. [PMID: 35131384 DOI: 10.1016/j.canlet.2022.215585] [Reference Citation Analysis]
20 Shi WQ, Liu WF, Li B, Lin Q, Li QH, Zhang YQ, Yuan Q, Liang RB, Ge QM, Shao Y. Assessment of Serum Tumor Markers for Predicting Ocular Metastasis in Lung Adenocarcinoma: A Retrospective Study. Dis Markers 2020;2020:2102158. [PMID: 32685054 DOI: 10.1155/2020/2102158] [Reference Citation Analysis]
21 Qi L, Knifley T, Piecoro DW, Rychahou P, Wu J, O'Connor KL, Chen M. In vivo Tumor Growth and Spontaneous Metastasis Assays Using A549 Lung Cancer Cells. Bio Protoc 2020;10:e3579. [PMID: 33659549 DOI: 10.21769/BioProtoc.3579] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
22 Rojko L, Megyesfalvi Z, Czibula E, Reiniger L, Teglasi V, Szegedi Z, Szallasi Z, Dome B, Moldvay J. Longitudinal analysis of complete blood count parameters in advanced-stage lung cancer patients. Thorac Cancer 2020;11:3193-204. [PMID: 32941706 DOI: 10.1111/1759-7714.13642] [Reference Citation Analysis]
23 Baik CS, Chamberlain MC, Chow LQ. Targeted Therapy for Brain Metastases in EGFR-Mutated and ALK-Rearranged Non-Small-Cell Lung Cancer. Journal of Thoracic Oncology 2015;10:1268-78. [DOI: 10.1097/jto.0000000000000615] [Cited by in Crossref: 39] [Cited by in F6Publishing: 27] [Article Influence: 5.6] [Reference Citation Analysis]
24 Cochran HC, Pandey Y, Nicholas RW, Del Giacco EJ, Mazin Safar A. Immune oncology (IO) and metastatic lung cancer [CBD]: Curability, bony metastasis and duration of therapy. Current Problems in Cancer: Case Reports 2021;4:100129. [DOI: 10.1016/j.cpccr.2021.100129] [Reference Citation Analysis]
25 Taniguchi Y, Tamiya A, Nakahama K, Naoki Y, Kanazu M, Omachi N, Okishio K, Kasai T, Atagi S. Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors. Oncol Lett 2017;14:7589-96. [PMID: 29344206 DOI: 10.3892/ol.2017.7125] [Cited by in Crossref: 3] [Cited by in F6Publishing: 11] [Article Influence: 0.6] [Reference Citation Analysis]
26 Sarkar D. Statins as Inhibitors of Lung Cancer Bone Metastasis. EBioMedicine 2017;19:6-7. [PMID: 28479040 DOI: 10.1016/j.ebiom.2017.04.028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
27 He ZY, Li MF, Lin JH, Lin D, Lin RJ. Comparing the efficacy of concurrent EGFR-TKI and whole-brain radiotherapy vs EGFR-TKI alone as a first-line therapy for advanced EGFR-mutated non-small-cell lung cancer with brain metastases: a retrospective cohort study. Cancer Manag Res 2019;11:2129-38. [PMID: 30936745 DOI: 10.2147/CMAR.S184922] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 3.7] [Reference Citation Analysis]
28 Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O’hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer 2019;128:105-12. [DOI: 10.1016/j.lungcan.2018.12.017] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 15.7] [Reference Citation Analysis]
29 Yu H, Zhao F, Li J, Zhu K, Lin H, Pan Z, Zhu M, Yao M, Yan M. TBX2 Identified as a Potential Predictor of Bone Metastasis in Lung Adenocarcinoma via Integrated Bioinformatics Analyses and Verification of Functional Assay. J Cancer 2020;11:388-402. [PMID: 31897234 DOI: 10.7150/jca.31636] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
30 Liu Q, Tong X, Wang J. Management of brain metastases: history and the present. Chin Neurosurg J 2019;5:1. [PMID: 32922901 DOI: 10.1186/s41016-018-0149-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
31 Tan C, Cho BC, Soo RA. Treatment options for EGFR mutant NSCLC with CNS involvement—Can patients BLOOM with the use of next generation EGFR TKIs? Lung Cancer 2017;108:29-37. [DOI: 10.1016/j.lungcan.2017.02.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 25] [Article Influence: 4.2] [Reference Citation Analysis]
32 Khan GJ, Sun L, Abbas M, Naveed M, Jamshaid T, Baig MMFA, Yuan S. In-vitro Pre-Treatment of Cancer Cells with TGF-β1: A Novel Approach of Tail Vein Lung Cancer Metastasis Mouse Model for Anti-Metastatic Studies. CMP 2019;12:249-60. [DOI: 10.2174/1874467212666190306165703] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
33 Lee JH, Kim IY, Kim YD, Lee SY, Jung JY. Navigation-guided percutaneous pelvic cementoplasty for metastatic bone pain: A case report. Medicine (Baltimore) 2021;100:e25521. [PMID: 33847672 DOI: 10.1097/MD.0000000000025521] [Reference Citation Analysis]
34 Zhou Y, Chen WZ, Peng AF, Tong WL, Liu JM, Liu ZL. Neuron-specific enolase, histopathological types, and age as risk factors for bone metastases in lung cancer. Tumour Biol 2017;39:1010428317714194. [PMID: 28671048 DOI: 10.1177/1010428317714194] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
35 Pagnotti GM, Trivedi T, Mohammad KS. Translational Strategies to Target Metastatic Bone Disease. Cells 2022;11:1309. [PMID: 35455987 DOI: 10.3390/cells11081309] [Reference Citation Analysis]
36 Li Z, Wei J, Cao H, Song M, Zhang Y, Jin Y. A predictive web-based nomogram for the early death of patients with lung adenocarcinoma and bone metastasis: a population-based study. J Int Med Res 2021;49:3000605211047771. [PMID: 34590874 DOI: 10.1177/03000605211047771] [Reference Citation Analysis]
37 Waisberg F, Lopez C, Enrico D, Rodriguez A, Hirsch I, Burton J, Mandó P, Martin C, Chacón M, Seetharamu N. Assessing the methodological quality of quality-of-life analyses in first-line non-small cell lung cancer trials: A systematic review. Crit Rev Oncol Hematol 2022;176:103747. [PMID: 35717006 DOI: 10.1016/j.critrevonc.2022.103747] [Reference Citation Analysis]
38 Wong CW, Ko LN, Huang HJ, Yang CS, Hsu SH. Engineered Bacteriorhodopsin May Induce Lung Cancer Cell Cycle Arrest and Suppress Their Proliferation and Migration. Molecules 2021;26:7344. [PMID: 34885925 DOI: 10.3390/molecules26237344] [Reference Citation Analysis]
39 Maeda T, Yamada D, Kawahara K. Cancer pain relief achieved by disrupting tumor-driven semaphorin 3A signaling in mice. Neuroscience Letters 2016;632:147-51. [DOI: 10.1016/j.neulet.2016.08.060] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
40 Xu Y, Li H, Weng L, Qiu Y, Zheng J, He H, Zheng D, Pan J, Wu F, Chen Y. Single nucleotide polymorphisms within the Wnt pathway predict the risk of bone metastasis in patients with non-small cell lung cancer. Aging (Albany NY) 2020;12:9311-27. [PMID: 32453708 DOI: 10.18632/aging.103207] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
41 Wang H, Ou Q, Li D, Qin T, Bao H, Hou X, Wang K, Wang F, Deng Q, Liang J, Zheng W, Wu X, Wang X, Shao YW, Mou Y, Chen L. Genes associated with increased brain metastasis risk in non–small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non–small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036). Cancer 2019;125:3535-44. [DOI: 10.1002/cncr.32372] [Cited by in Crossref: 21] [Cited by in F6Publishing: 26] [Article Influence: 7.0] [Reference Citation Analysis]
42 Wu H, Shang LQ, Chen RL, Yang SM, Wang SL, Wang J, Sun G. Significance of Trask protein interactions in brain metastatic cohorts of lung cancers. Tumour Biol 2015;36:4181-7. [PMID: 25775948 DOI: 10.1007/s13277-015-3053-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
43 Yeh KL, Wu SH, Wu SS. Isolated distal ulnar bone metastasis from lung squamous cell carcinoma: an extremely rare case report. J Int Med Res 2021;49:300060521998875. [PMID: 33736505 DOI: 10.1177/0300060521998875] [Reference Citation Analysis]
44 Liu K, Jiang G, Zhang A, Li Z, Jia J. Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer. BMC Cancer 2020;20:76. [PMID: 32000711 DOI: 10.1186/s12885-020-6543-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
45 Stecco A, Trisoglio A, Soligo E, Berardo S, Sukhovei L, Carriero A. Whole-Body MRI with Diffusion-Weighted Imaging in Bone Metastases: A Narrative Review. Diagnostics (Basel) 2018;8:E45. [PMID: 29987207 DOI: 10.3390/diagnostics8030045] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 5.0] [Reference Citation Analysis]
46 Liu W, Zhou W, Qi WL, Ma YD, Xu YY. Gastrointestinal hemorrhage due to ileal metastasis from primary lung cancer. World J Gastroenterol 2015; 21(11): 3435-3440 [PMID: 25805957 DOI: 10.3748/wjg.v21.i11.3435] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
47 Ragab Shalaby AM, Kazuei H, Koichi H, Naguib S, Al-Menawei LA. Assessment of intracranial metastases from neuroendocrine tumors/carcinoma. J Neurosci Rural Pract 2016;7:435-9. [PMID: 27365963 DOI: 10.4103/0976-3147.182779] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
48 Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol 2018;35:71. [PMID: 29651632 DOI: 10.1007/s12032-018-1132-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
49 Ruzycka M, Cimpan MR, Rios-Mondragon I, Grudzinski IP. Microfluidics for studying metastatic patterns of lung cancer. J Nanobiotechnology 2019;17:71. [PMID: 31133019 DOI: 10.1186/s12951-019-0492-0] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 9.0] [Reference Citation Analysis]
50 Wang H, Zhang W, Bado I, Zhang XH. Bone Tropism in Cancer Metastases. Cold Spring Harb Perspect Med 2020;10:a036848. [PMID: 31615871 DOI: 10.1101/cshperspect.a036848] [Reference Citation Analysis]
51 Zhang Y, Tang H, Li J, Li M. An active treatment of lung adenocarcinoma cancer with brain metastases: icotinib. Onco Targets Ther 2015;8:1351-4. [PMID: 26089684 DOI: 10.2147/OTT.S78925] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
52 Liu Y, Wang J, Wu J, Yang Q, Zeng Y, Wu D, Tian C, Hu Y, Gu F, Li C, Zhang K, Liu L. The Efficacy of First-Generation EGFR-TKI Combined With Brain Radiotherapy as the First-Line Treatment for Lung Adenocarcinoma Patients With Brain Metastases and EGFR Sensitive Mutations: A Retrospective study. Technol Cancer Res Treat 2021;20:1533033821997819. [PMID: 33715525 DOI: 10.1177/1533033821997819] [Reference Citation Analysis]
53 Yang P, Leu D, Ye K, Srinivasan C, Fike JR, Huang TT. Cognitive impairments following cranial irradiation can be mitigated by treatment with a tropomyosin receptor kinase B agonist. Exp Neurol 2016;279:178-86. [PMID: 26946222 DOI: 10.1016/j.expneurol.2016.02.021] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
54 Jiang L, Jung S, Zhao J, Kasinath V, Ichimura T, Joseph J, Fiorina P, Liss AS, Shah K, Annabi N, Joshi N, Akama TO, Bromberg JS, Kobayashi M, Uchimura K, Abdi R. Simultaneous targeting of primary tumor, draining lymph node, and distant metastases through high endothelial venule-targeted delivery. Nano Today 2021;36:101045. [PMID: 33391389 DOI: 10.1016/j.nantod.2020.101045] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
55 Li SH, Hsieh MH, Fang YF. Afatinib in Treatment-Naive Patients With EGFR-Mutated Lung Adenocarcinoma With Brain Metastasis: A Case Series. Medicine (Baltimore) 2015;94:e1739. [PMID: 26469914 DOI: 10.1097/MD.0000000000001739] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Wu DM, Liu T, Deng SH, Han R, Zhang T, Li J, Xu Y. Alpha-1 Antitrypsin Induces Epithelial-to-Mesenchymal Transition, Endothelial-to-Mesenchymal Transition, and Drug Resistance in Lung Cancer Cells. Onco Targets Ther 2020;13:3751-63. [PMID: 32440144 DOI: 10.2147/OTT.S242579] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
57 Ren Y, Dai C, Zheng H, Zhou F, She Y, Jiang G, Fei K, Yang P, Xie D, Chen C. Prognostic effect of liver metastasis in lung cancer patients with distant metastasis. Oncotarget. 2016;7:53245-53253. [PMID: 27449299 DOI: 10.18632/oncotarget.10644] [Cited by in Crossref: 62] [Cited by in F6Publishing: 65] [Article Influence: 15.5] [Reference Citation Analysis]
58 Trinh CT, Nguyen TTT, Van HAT, Hoang VT. A Rare Case of Diffuse Subependymal Periventricular Metastases from Small Cell Lung Carcinoma. Case Rep Oncol 2020;13:1304-10. [PMID: 33250746 DOI: 10.1159/000508828] [Reference Citation Analysis]
59 Kashima J, Okuma Y, Miwa M, Hosomi Y. Survival of patients with brain metastases from non-small cell lung cancer harboring EGFR mutations treated with epidermal growth factor receptor tyrosine kinase inhibitors. Med Oncol 2016;33:129. [PMID: 27757781 DOI: 10.1007/s12032-016-0843-8] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
60 Gomi D, Fukushima T, Kobayashi T, Sekiguchi N, Koizumi T, Oguchi K. Fluorine-18-fluorodeoxyglucose-positron emission tomography evaluation in metastatic bone lesions in lung cancer: Possible prediction of pain and skeletal-related events. Thorac Cancer 2019;10:980-7. [PMID: 30883012 DOI: 10.1111/1759-7714.13041] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
61 Fu F, Zhang Y, Gao Z, Zhao Y, Wen Z, Han H, Li Y, Chen H. Development and validation of a five-gene model to predict postoperative brain metastasis in operable lung adenocarcinoma. Int J Cancer 2020;147:584-92. [PMID: 32181877 DOI: 10.1002/ijc.32981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
62 Su PL, Wu YL, Chang WY, Ho CL, Tseng YL, Lai WW, Su WC, Lin CC, Yang SC. Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer. Ther Adv Med Oncol 2018;10:1758835918797589. [PMID: 30263066 DOI: 10.1177/1758835918797589] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
63 Winther-Larsen A, Hviid CVB, Meldgaard P, Sorensen BS, Sandfeld-Paulsen B. Neurofilament Light Chain as A Biomarker for Brain Metastases. Cancers (Basel) 2020;12:E2852. [PMID: 33023150 DOI: 10.3390/cancers12102852] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
64 Radeczky P, Megyesfalvi Z, Laszlo V, Fillinger J, Moldvay J, Raso E, Schlegl E, Barbai T, Timar J, Renyi-Vamos F, Dome B, Hegedus B. The effects of bisphosphonate and radiation therapy in bone-metastatic lung adenocarcinoma: the impact of KRAS mutation. Transl Lung Cancer Res 2021;10:675-84. [PMID: 33718013 DOI: 10.21037/tlcr-20-754] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
65 Chua KN, Kong LR, Sim WJ, Ng HC, Ong WR, Thiery JP, Huynh H, Goh BC. Combinatorial treatment using targeted MEK and SRC inhibitors synergistically abrogates tumor cell growth and induces mesenchymal-epithelial transition in non-small-cell lung carcinoma. Oncotarget 2015;6:29991-30005. [PMID: 26358373 DOI: 10.18632/oncotarget.5031] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
66 Adashek ML, Miller K, Silpasuvan AA. EGFR T790M-Positive Lung Adenocarcinoma Metastases to the Pituitary Gland Causing Adrenal Insufficiency: A Case Report. Case Rep Oncol Med 2018;2018:2349021. [PMID: 29955407 DOI: 10.1155/2018/2349021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
67 Adjei IM, Temples MN, Brown SB, Sharma B. Targeted Nanomedicine to Treat Bone Metastasis. Pharmaceutics 2018;10:E205. [PMID: 30366428 DOI: 10.3390/pharmaceutics10040205] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 4.3] [Reference Citation Analysis]
68 Wang X, Liu H, Shen K, Pan X, Wei Y, Lv T, Song Y. Long intergenic non‑coding RNA 00467 promotes lung adenocarcinoma proliferation, migration and invasion by binding with EZH2 and repressing HTRA3 expression. Mol Med Rep 2019;20:640-54. [PMID: 31180543 DOI: 10.3892/mmr.2019.10292] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
69 Wang M, Wu Q, Zhang J, Qin G, Yang T, Liu Y, Wang X, Zhang B, Wei Y. Prognostic impacts of extracranial metastasis on non-small cell lung cancer with brain metastasis: A retrospective study based on surveillance, epidemiology, and end results database. Cancer Med 2021;10:471-82. [PMID: 33320433 DOI: 10.1002/cam4.3562] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
70 Oh TI, Lee M, Lee YM, Kim GH, Lee D, You JS, Kim SH, Choi M, Jang H, Park YM, Shin HW, Shin DH, Lim JH. PGC1α Loss Promotes Lung Cancer Metastasis through Epithelial-Mesenchymal Transition. Cancers (Basel) 2021;13:1772. [PMID: 33917757 DOI: 10.3390/cancers13081772] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
71 Tozuka T, Kitazono S, Sakamoto H, Yoshida H, Amino Y, Uematsu S, Yoshizawa T, Hasegawa T, Ariyasu R, Uchibori K, Yanagitani N, Horai T, Seike M, Gemma A, Nishio M. Poor efficacy of anti-programmed cell death-1/ligand 1 monotherapy for non-small cell lung cancer patients with active brain metastases. Thorac Cancer 2020;11:2465-72. [PMID: 32657011 DOI: 10.1111/1759-7714.13557] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
72 Che J, Shen WZ, Deng Y, Dai YH, Liao YD, Yuan XL, Zhang P. Effects of lentivirus-mediated silencing of Periostin on tumor microenvironment and bone metastasis via the integrin-signaling pathway in lung cancer. Life Sci 2017;182:10-21. [PMID: 28601389 DOI: 10.1016/j.lfs.2017.05.030] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
73 Ihn HJ, Kim JA, Bae YC, Shin HI, Baek MC, Park EK. Afatinib ameliorates osteoclast differentiation and function through downregulation of RANK signaling pathways. BMB Rep 2017;50:150-5. [PMID: 28256196 DOI: 10.5483/bmbrep.2017.50.3.223] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
74 Hung MS, Chen IC, Lee CP, Huang RJ, Chen PC, Tsai YH, Yang YH. Statin improves survival in patients with EGFR-TKI lung cancer: A nationwide population-based study. PLoS One 2017;12:e0171137. [PMID: 28158206 DOI: 10.1371/journal.pone.0171137] [Cited by in Crossref: 31] [Cited by in F6Publishing: 34] [Article Influence: 6.2] [Reference Citation Analysis]
75 Chen H, Wu A, Tao H, Yang D, Luo Y, Li S, Yang Z, Chen M. Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis. Medicine (Baltimore) 2018;97:e13014. [PMID: 30383657 DOI: 10.1097/MD.0000000000013014] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
76 Hakim M, Kermanshah L, Abouali H, Hashemi HM, Yari A, Khorasheh F, Alemzadeh I, Vossoughi M. Unraveling Cancer Metastatic Cascade Using Microfluidics-based Technologies. Biophys Rev. [DOI: 10.1007/s12551-022-00944-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Bae MK, Yu WS, Byun GE, Lee CY, Lee JG, Kim DJ, Chung KY. Prognostic factors for cases with no extracranial metastasis in whom brain metastasis is detected after resection of non-small cell lung cancer. Lung Cancer 2015;88:195-200. [PMID: 25770646 DOI: 10.1016/j.lungcan.2015.02.013] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
78 Lee HH, Chen CH, Chuang HY, Huang YW, Huang MY. Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases. Sci Rep 2019;9:16834. [PMID: 31728013 DOI: 10.1038/s41598-019-53456-z] [Reference Citation Analysis]
79 Deligiorgi MV, Trafalis DT. Repurposing denosumab in lung cancer beyond counteracting the skeletal related events: an intriguing perspective. Expert Opin Biol Ther 2020;20:1331-46. [PMID: 32658547 DOI: 10.1080/14712598.2020.1790522] [Reference Citation Analysis]
80 Aramwit P, Porasuphatana S, Srichana T, Nakpheng T. Toxicity evaluation of cordycepin and its delivery system for sustained in vitro anti-lung cancer activity. Nanoscale Res Lett 2015;10:152. [PMID: 25883541 DOI: 10.1186/s11671-015-0851-1] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
81 Beer L, Jajodia A, Prosch H. Pearls and pitfalls in lung cancer staging. BJR Open 2020;2:20200019. [PMID: 33178978 DOI: 10.1259/bjro.20200019] [Reference Citation Analysis]
82 Megyesfalvi Z, Tallosy B, Pipek O, Fillinger J, Lang C, Klikovits T, Schwendenwein A, Hoda MA, Renyi-Vamos F, Laszlo V, Rezeli M, Moldvay J, Dome B. The landscape of small cell lung cancer metastases: Organ specificity and timing. Thorac Cancer 2021;12:914-23. [PMID: 33533174 DOI: 10.1111/1759-7714.13854] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
83 Stefanou D, Stamatopoulou S, Sakellaropoulou A, Akakios G, Gkiaouraki M, Gkeka D, Prevezanou M, Ardavanis A. Bevacizumab, pemetrexed and carboplatin in first-line treatment of non-small cell lung cancer patients: Focus on patients with brain metastases. Oncol Lett 2016;12:4635-42. [PMID: 28101218 DOI: 10.3892/ol.2016.5268] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
84 Guo QM, Wang L, Yu WJ, Qiao LH, Zhao MN, Hu XM, Sun YM, Ni S, Xu YH, Lou JT. Detection of Plasma EGFR Mutations in NSCLC Patients with a Validated ddPCR Lung cfDNA Assay. J Cancer 2019;10:4341-9. [PMID: 31413754 DOI: 10.7150/jca.31326] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
85 Muralidharan R, Babu A, Amreddy N, Srivastava A, Chen A, Zhao YD, Kompella UB, Munshi A, Ramesh R. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth In Vitro and In Vivo By Disrupting the Oncogenic Activity of the RNA-binding Protein HuR. Mol Cancer Ther 2017;16:1470-86. [PMID: 28572169 DOI: 10.1158/1535-7163.MCT-17-0134] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
86 Sun YW, Xu J, Zhou J, Liu WJ. Targeted drugs for systemic therapy of lung cancer with brain metastases. Oncotarget 2018;9:5459-72. [PMID: 29435193 DOI: 10.18632/oncotarget.23616] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 5.2] [Reference Citation Analysis]
87 Wang X, Mao W, Wang Z, Li X, Xiong Y, Lu H, Wang X, Yin H, Cao X, Xin H. Enhanced Anti-Brain Metastasis from Non-Small Cell Lung Cancer of Osimertinib and Doxorubicin Co-Delivery Targeted Nanocarrier. Int J Nanomedicine 2020;15:5491-501. [PMID: 32848385 DOI: 10.2147/IJN.S258699] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
88 Lo Russo G, Imbimbo M, Corrao G, Proto C, Signorelli D, Vitali M, Ganzinelli M, Botta L, Zilembo N, de Braud F, Garassino MC. Concomitant EML4-ALK rearrangement and EGFR mutation in non-small cell lung cancer patients: a literature review of 100 cases. Oncotarget 2017;8:59889-900. [PMID: 28938691 DOI: 10.18632/oncotarget.17431] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 4.2] [Reference Citation Analysis]
89 Brouns A, Dursun S, Bootsma G, Dingemans AC, Hendriks L. Reporting of Incidence and Outcome of Bone Metastases in Clinical Trials Enrolling Patients with Epidermal Growth Factor Receptor Mutated Lung Adenocarcinoma-A Systematic Review. Cancers (Basel) 2021;13:3144. [PMID: 34201833 DOI: 10.3390/cancers13133144] [Reference Citation Analysis]
90 Zhou X, Li X, Sun C, Shi C, Hua D, Yu L, Wen Y, Hua F, Wang Q, Zhou Q, Yu S. Quaking-5 suppresses aggressiveness of lung cancer cells through inhibiting β-catenin signaling pathway. Oncotarget 2017;8:82174-84. [PMID: 29137254 DOI: 10.18632/oncotarget.19066] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 3.8] [Reference Citation Analysis]
91 Shao H, Wang L, Lin T, Zhang Y, Zhang Z. Effect of protamine on Fe 3 O 4 @CS@GFTN composite magnetic nanoparticles. Funct Mater Lett 2020;13:2050001. [DOI: 10.1142/s1793604720500010] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
92 Yu X, Fan Y. Effect of pemetrexed on brain metastases from nonsmall cell lung cancer with wild-type and unknown EGFR status. Medicine (Baltimore) 2019;98:e14110. [PMID: 30653134 DOI: 10.1097/MD.0000000000014110] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
93 Aiko N, Shimokawa T, Miyazaki K, Misumi Y, Agemi Y, Ishii M, Nakamura Y, Yamanaka T, Okamoto H. Comparison of the efficacies of first-generation epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in patients with advanced non-small-cell lung cancer harboring EGFR mutations. BMC Cancer 2018;18:1012. [PMID: 30348116 DOI: 10.1186/s12885-018-4911-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
94 Hu F, Xu J, Zhang B, Li C, Nie W, Gu P, Hu P, Wang H, Zhang Y, Shen Y, Wang S, Zhang X. Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring Epidermal Growth Factor Receptor Mutations. Clin Lung Cancer. 2019;20:e81-e90. [PMID: 30341018 DOI: 10.1016/j.cllc.2018.09.010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 4.0] [Reference Citation Analysis]
95 Guan J, Chen M, Xiao N, Li L, Zhang Y, Li Q, Yang M, Liu L, Chen L. EGFR mutations are associated with higher incidence of distant metastases and smaller tumor size in patients with non-small-cell lung cancer based on PET/CT scan. Med Oncol 2016;33:1. [PMID: 26589606 DOI: 10.1007/s12032-015-0714-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 4.0] [Reference Citation Analysis]
96 Liu X, Li H, Liu J, Guan Y, Huang L, Tang H, He J. Immune reconstitution from peripheral blood mononuclear cells inhibits lung carcinoma growth in NOD/SCID mice. Oncol Lett 2014;8:1638-44. [PMID: 25202383 DOI: 10.3892/ol.2014.2379] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
97 Jin Y, Xin T. [Research Progress of EGFR-TKI Therapy for Patients with Central Nervous System 
Metastases from Non-small Cell Lung Cancer]. Zhongguo Fei Ai Za Zhi 2016;19:496-500. [PMID: 27561797 DOI: 10.3779/j.issn.1009-3419.2016.08.02] [Reference Citation Analysis]
98 Yousuf S, Brat DJ, Shu H, Wang Y, Stein DG, Atif F. Progesterone improves neurocognitive outcomes following therapeutic cranial irradiation in mice. Hormones and Behavior 2017;96:21-30. [DOI: 10.1016/j.yhbeh.2017.08.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
99 Xu J, Liu X, Yang S, Zhang X, Shi Y. Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma. Onco Targets Ther 2016;9:2911-7. [PMID: 27274284 DOI: 10.2147/OTT.S102472] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
100 Drosos E, Kalyvas A, Komaitis S, Skandalakis GP, Kalamatianos T, Liouta E, Neromyliotis E, Alexiou GA, Stranjalis G, Koutsarnakis C. Angiosarcoma-related cerebral metastases: a systematic review of the literature. Neurosurg Rev 2020;43:1019-38. [PMID: 31165296 DOI: 10.1007/s10143-019-01127-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
101 Kanehira Y, Togami K, Tada H, Chono S. Tumor distribution and anti-tumor effect of doxorubicin following intrapulmonary administration to mice with metastatic lung tumor. Journal of Drug Delivery Science and Technology 2016;33:143-8. [DOI: 10.1016/j.jddst.2016.04.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.2] [Reference Citation Analysis]
102 Venur VA, Ahluwalia MS. Targeted Therapy in Brain Metastases: Ready for Primetime? American Society of Clinical Oncology Educational Book 2016. [DOI: 10.1200/edbk_100006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
103 Fang XQ, Lee M, Lim WJ, Lee S, Lim CH, Lim JH. PGC1α Cooperates with FOXA1 to Regulate Epithelial Mesenchymal Transition through the TCF4-TWIST1. Int J Mol Sci 2022;23:8247. [PMID: 35897813 DOI: 10.3390/ijms23158247] [Reference Citation Analysis]
104 Zang X, Qian C, Ruan Y, Xie J, Luo T, Xu B, Jiang J. Higher maternal embryonic leucine zipper kinase mRNA expression level is a poor prognostic factor in non-small-cell lung carcinoma patients. Biomark Med 2019;13:1349-61. [PMID: 31599664 DOI: 10.2217/bmm-2019-0052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
105 Akimoto J, Fukuhara H, Suda T, Nagai K, Ichikawa M, Fukami S, Kohno M, Matsubayashi J, Nagao T. Clinicopathological analysis in patients with neuroendocrine tumors that metastasized to the brain. BMC Cancer 2016;16:36. [PMID: 26801624 DOI: 10.1186/s12885-015-1999-x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
106 Yamada D, Kawahara K, Maeda T. mTORC1 is a critical mediator of oncogenic Semaphorin3A signaling. Biochemical and Biophysical Research Communications 2016;476:475-80. [DOI: 10.1016/j.bbrc.2016.05.147] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
107 Yang J, Zhang Y, Sun X, Gusdon AM, Song N, Chen L, Jiang G, Huang Y. The prognostic value of multiorgan metastases in patients with non-small cell lung cancer and its variants: a SEER-based study. J Cancer Res Clin Oncol 2018;144:1835-42. [PMID: 30003315 DOI: 10.1007/s00432-018-2702-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 18] [Article Influence: 3.8] [Reference Citation Analysis]
108 Schmid-Alliana A, Schmid-Antomarchi H, Al-Sahlanee R, Lagadec P, Scimeca JC, Verron E. Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. Int J Mol Sci 2018;19:E148. [PMID: 29300334 DOI: 10.3390/ijms19010148] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
109 Batista N, Tee J, Sciubba D, Sahgal A, Laufer I, Weber M, Gokaslan Z, Rhines L, Fehlings M, Patel S, Raja Rampersaud Y, Reynolds J, Chou D, Bettegowda C, Clarke M, Fisher C. Emerging and established clinical, histopathological and molecular parametric prognostic factors for metastatic spine disease secondary to lung cancer: Helping surgeons make decisions. Journal of Clinical Neuroscience 2016;34:15-22. [DOI: 10.1016/j.jocn.2016.05.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
110 Wei M, Feng S, Zhang L, Wang C, Chu S, Shi T, Zhou W, Zhang Y. Active Fraction Combination From Liuwei Dihuang Decoction Improves Adult Hippocampal Neurogenesis and Neurogenic Microenvironment in Cranially Irradiated Mice. Front Pharmacol 2021;12:717719. [PMID: 34630096 DOI: 10.3389/fphar.2021.717719] [Reference Citation Analysis]
111 Cui Z, Liu Z, Zeng J, Zhang S, Chen L, Zhang G, Xu W, Song L, Guo X. TRIM59 promotes gefitinib resistance in EGFR mutant lung adenocarcinoma cells. Life Sci 2019;224:23-32. [PMID: 30902544 DOI: 10.1016/j.lfs.2019.03.041] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
112 Sharma JK, Kataria R, Choudhary M, Purohit DK. Differential Diagnosis of Calvarial Tumors: A Series of 8 Cases. Indian Journal of Neurosurgery. [DOI: 10.1055/s-0041-1722828] [Reference Citation Analysis]
113 Higuchi T, Sugisawa N, Park JH, Sun Y, Zhu G, Yamamoto N, Hayashi K, Kimura H, Miwa S, Igarashi K, Bouvet M, Singh SR, Tsuchiya H, Hoffman RM. Osimertinib regressed an EGFR-mutant lung-adenocarcinoma bone-metastasis mouse model and increased long-term survival. Transl Oncol 2020;13:100826. [PMID: 32659740 DOI: 10.1016/j.tranon.2020.100826] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
114 Sá Pinto A, Alves VM, Oliveira A, Castro RH, Pereira JG. Incidental finding of a monostotic form of Paget Disease of the scapula in a lung cancer patient. Radiography (Lond) 2017;23:e72-4. [PMID: 28687305 DOI: 10.1016/j.radi.2017.02.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
115 Radeczky P, Moldvay J, Fillinger J, Szeitz B, Ferencz B, Boettiger K, Rezeli M, Bogos K, Renyi-Vamos F, Hoetzenecker K, Hegedus B, Megyesfalvi Z, Dome B. Bone-Specific Metastasis Pattern of Advanced-Stage Lung Adenocarcinoma According to the Localization of the Primary Tumor. Pathol Oncol Res 2021;27:1609926. [PMID: 34629961 DOI: 10.3389/pore.2021.1609926] [Reference Citation Analysis]
116 Gomes M, Archer F, Girard N, Gineys B, Dolmazon C, Bobet Erny A, Mornex JF, Leroux C. Blocked expression of key genes of the angiogenic pathway in JSRV-induced pulmonary adenocarcinomas. Vet Res 2017;48:76. [PMID: 29137669 DOI: 10.1186/s13567-017-0480-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
117 Xu Y, Vagnerova K. Anesthetic Management of Asleep and Awake Craniotomy for Supratentorial Tumor Resection. Anesthesiol Clin 2021;39:71-92. [PMID: 33563387 DOI: 10.1016/j.anclin.2020.11.007] [Reference Citation Analysis]
118 Ren B, Zou L, Guo Q, Tian Y. Survival and effective prognostic factors in lung cancer patients with brain metastases treated with whole brain radiotherapy. Radiation Medicine and Protection 2021;2:5-12. [DOI: 10.1016/j.radmp.2021.01.001] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
119 Huang F, Cao Y, Wang C, Lan R, Wu B, Xie X, Hong J, Fu L, Wu G. PNMA5 Promotes Bone Metastasis of Non-small-Cell Lung Cancer as a Target of BMP2 Signaling. Front Cell Dev Biol 2021;9:678931. [PMID: 34136487 DOI: 10.3389/fcell.2021.678931] [Reference Citation Analysis]
120 Han Y, Zhang X, Lu Y, Dong Y, Fu H, Zhang B, Gao Y. Elemene treatment for NSCLC with multiple CNS metastases: a case report and literature review. Onco Targets Ther 2018;11:6377-82. [PMID: 30323615 DOI: 10.2147/OTT.S160970] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
121 Hung MS, Chuang MC, Chen YC, Lee CP, Yang TM, Chen PC, Tsai YH, Yang YH. Metformin Prolongs Survival in Type 2 Diabetes Lung Cancer Patients With EGFR-TKIs. Integr Cancer Ther 2019;18:1534735419869491. [PMID: 31409137 DOI: 10.1177/1534735419869491] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]